drugset / Trial / NCT00440531

Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

NCT00440531

Phase 3 Completed 540 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this trial is to determine if there is an improvement in the immune response of older adults over 50 years of age using a modified process hepatitis B vaccine and a currently licensed hepatitis B vaccine (RECOMBIVAX HB™).

Timeline

Start
2006-11
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Engerix-B Vaccine 20 ug Intramuscular
Comparator HEPLISAV-B Vaccine 10 ug Intramuscular
Subject Modified Process Hepatitis B Vaccine Vaccine 10 ug Intramuscular